Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

10 evidence topics · 16 sources

APOL1-directed and other investigational therapies for AMKD: review table
MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results

“today announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).” (opens the source at this quote in a new tab)

“The HORIZON study is a Phase 2, open-label basket design trial that enrolled patients with broad AMKD carrying the APOL1 high risk genotype, including diabetic and non-diabetic patients and non-diabetic patients with severe focal segmental glomerulosclerosis (FSGS).” (opens the source at this quote in a new tab)

“For this topline analysis, 15 patients were enrolled in the HORIZON study and all were included in a safety and tolerability analysis. Twelve patients were evaluated for efficacy, i.e., uACR reduction, based on meeting the per protocol compliance threshold.” (opens the source at this quote in a new tab)

“Across all evaluated patients, a mean reduction in proteinuria from baseline of 35.6% was observed and 50% of patients achieved at least a 30% reduction in uACR.” (opens the source at this quote in a new tab)

“In FSGS patients, treatment with MZE829 led to a mean reduction in uACR of 61.8%. In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%. In patients with AMKD with diabetes, five patients were evaluable per protocol for efficacy, with two patients achieving at least a 30% reduction in uACR.” (opens the source at this quote in a new tab)

“No serious adverse events (AEs) or severe treatment-related adverse events (TRAEs) were observed.” (opens the source at this quote in a new tab)